Content
03/05/2025
New York, NY USA
Ataraxis AI
completed $20.4 million Series A Round funding. Investors include
AIX Ventures (lead), Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, Giant Ventures, Obvious Ventures.
About
Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. The company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Ataraxis’ first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays.
Startup
Sector:
AI
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
